# Brain Imaging Study Of Rosiglitazone Efficacy And Safety In Alzheimer's Disease

> **NCT00265148** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 80 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** Rosiglitazone
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00265148
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-05-18
- **Primary completion:** 2008-07-10
- **Final completion:** 2008-07-10
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2020-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00265148

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00265148, "Brain Imaging Study Of Rosiglitazone Efficacy And Safety In Alzheimer's Disease". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00265148. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*